The Efficacy of Intravitreal Bevacizumab in the Treatment of Macular Edema.

Moon, Sun Kyung; Lee, Soo Young; Lee, Jeong Hee

doi:2009.50.8.1232

J Korean Ophthalmol Soc > Volume 50(8); 2009 > Article

Original Article

Journal of the Korean Ophthalmological Society 2009;50(8):1232-1236.
DOI: https://doi.org/10.3341/jkos.2009.50.8.1232 Published online August 15, 2009.

The Efficacy of Intravitreal Bevacizumab in the Treatment of Macular Edema.

Sun Kyung Moon, Soo Young Lee, Jeong Hee Lee

¹Department of Ophthalmology, School of Medicine, Ewha Womans University, Seoul, Korea. leejhoph@ewha.ac.kr
²Department of Ophthalmology, National Medical Center, Seoul, Korea.

황반부종에 대한 베바시주맙 유리체강내 주사의 효과

문선경¹ ㆍ이수영² ㆍ이정희¹

Department of Ophthalmology, School of Medicine, Ewha Womans University¹ , Seoul, Korea / Department of Ophthalmology, National Medical Center² , Seoul, Korea

Abstract

PURPOSE
To investigate the efficacy in best corrected visual acuity (BCVA) and central macularthickness after intravitreal bevacizumab injection in patients with macular edema. METHODS: Patients with macular edema due to branch retinal vein occlusion, central retinal vein occlusion, and diabetic retinopathy received intravitreal injection of bevacizumab (2.5 mg/0.1cc). Complete ophthalmic examinations including best corrected visual acuity and optical coherence tomography (OCT) were performed at baseline and follow-up visits for 6 months. RESULTS: In macular edema secondary to branch retinal vein occlusion, the mean BCVA improved from logMAR 0.62+/-0.30 at baseline to logMAR 0.43+/-0.37 at 1 month, 0.34+/-0.40 at 3 months and 0.38+/-0.37 at 6 months (p<0.05). The mean central macular thickness decreased from 451.2+/-118.9 micrometer at baseline to 280.3+/-124.6 micrometer at 1 month, 345.8+/-157.1 micrometer at 3 months and 312.9+/-174.4 micrometer at 6 months (p<0.05). In macular edema secondary to central retinal vein occlusion and diabetic retinopathy, visual improvement and macular thickness reduction were not statistically significant. CONCLUSIONS: Intravitreal bevacizumab injection appears to be more effective for macular edema due to branch retinal vein occlusion than macular edema secondary to central retinal vein occlusion and diabetic retinopathy.

Key Words: Bavacizumab;Diabetic retinopathy;Macular edema;Retinal vein occlusion